Previous Close | 481.10 |
Open | 484.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 478.70 - 487.40 |
52 Week Range | 308.60 - 559.40 |
Volume | |
Avg. Volume | 204,327 |
Market Cap | 34.638B |
Beta (5Y Monthly) | 0.63 |
PE Ratio (TTM) | 54.03 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 4.00 (0.83%) |
Ex-Dividend Date | May 13, 2024 |
1y Target Est | N/A |
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.